Change in Patients' Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360
Anna Barata(Massachusetts General Hospital), Heather Jim(Moffitt Cancer Center), Michael D. Jain(Moffitt Cancer Center), Aleksandr Lazaryan(Moffitt Cancer Center), Laura B. Oswald(Moffitt Cancer Center), Yvelise Rodriguez(Moffitt Cancer Center), Kelly A. Hyland(University of South Florida), Margaret Booth‐Jones(Moffitt Cancer Center), Frederick L. Locke(Moffitt Cancer Center), Bijal Shah(Boston College), Anuhya Kommalapati(University of South Carolina), Reena Jayani(Vanderbilt University Medical Center), Kedar Kirtane(Moffitt Cancer Center), Nathaly Irizarry‐Arroyo(Moffitt Cancer Center), Jennifer M. Logue(Moffitt Cancer Center), Sarah L. Eisel(Moffitt Cancer Center), Taylor Welniak(Moffitt Cancer Center), Julio C. Chávez(Moffitt Cancer Center), Aasha I. Hoogland(Moffitt Cancer Center), Brent J. Small(University of North Carolina at Chapel Hill), Sepideh Mokhtari(Moffitt Cancer Center), Brian D. Gonzalez(Moffitt Cancer Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k